Short Interest in NewLink Genetics Corp (NASDAQ:NLNK) Expands By 14.2%
NewLink Genetics Corp (NASDAQ:NLNK) saw a significant increase in short interest in July. As of July 31st, there was short interest totalling 1,493,800 shares, an increase of 14.2% from the June 30th total of 1,307,600 shares. Based on an average trading volume of 384,600 shares, the short-interest ratio is currently 3.9 days. Currently, 5.2% of the shares of the company are sold short.
Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC lifted its stake in NewLink Genetics by 25.7% in the first quarter. Acadian Asset Management LLC now owns 404,083 shares of the biotechnology company’s stock valued at $780,000 after purchasing an additional 82,579 shares during the last quarter. Two Sigma Advisers LP lifted its position in shares of NewLink Genetics by 22.6% during the fourth quarter. Two Sigma Advisers LP now owns 110,000 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 20,300 shares in the last quarter. Pennsylvania Trust Co purchased a new stake in shares of NewLink Genetics during the first quarter worth $48,000. Virtu Financial LLC purchased a new stake in shares of NewLink Genetics during the first quarter worth $60,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of NewLink Genetics by 31.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 375,866 shares of the biotechnology company’s stock worth $571,000 after acquiring an additional 89,528 shares in the last quarter. Institutional investors and hedge funds own 33.72% of the company’s stock.
Several research firms have recently issued reports on NLNK. ValuEngine raised NewLink Genetics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Saturday, August 3rd.
NewLink Genetics (NASDAQ:NLNK) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. NewLink Genetics had a negative return on equity of 33.23% and a negative net margin of 6,587.56%. The business had revenue of $0.15 million for the quarter. On average, equities research analysts forecast that NewLink Genetics will post -0.03 EPS for the current fiscal year.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
Further Reading: Cost of Goods Sold (COGS)
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.